Inspire Medical Systems has pioneered a disruptive, FDA-approved therapy for obstructive sleep apnea (OSA), targeting the large segment of moderate-to-severe patients unable to tolerate CPAP. The company’s proprietary neurostimulator offers a minimally invasive, mask-free solution—delivered to over 100,000 patients as of early 2025 and now available at more than 1,300 centers in the US and select international markets. With strong clinical validation, widespread insurance reimbursement, and a high-margin business model, Inspire is scaling its therapy globally. The patient pool is vast (over 100 million have OSA globally, with millions intolerant to CPAP), and Inspire’s solution directly addresses this unmet need. After years of rapid expansion, the company now faces a more mature phase: growth has moderated to the teens and profitability is emerging, while competition, market saturation, and macro trends like GLP-1 adoption begin to shape the outlook.